71777-70-3

Usage

Uses

Used in Scientific Research:
4-Ethoxy-2-pyridinecarboxylic acid ethyl ester is used as a research compound for [application reason] in the field of organic chemistry. Its unique structure and properties make it a valuable tool for studying various chemical reactions and processes.
Used in Industrial Applications:
4-Ethoxy-2-pyridinecarboxylic acid ethyl ester is used as an intermediate or reagent in the synthesis of other compounds for [application reason] in various industries. Its presence in the family of Pyridinecarboxylic Acids and derivatives suggests potential applications in the production of pharmaceuticals, agrochemicals, or other specialty chemicals.
Note: Since the provided materials do not specify the exact applications or reasons for using 4-Ethoxy-2-pyridinecarboxylic acid ethyl ester, the placeholders [application reason] are used to indicate where more specific information would be required to complete the sentence.

InChI:InChI=1/C10H13NO3/c1-3-13-8-5-6-11-9(7-8)10(12)14-4-2/h5-7H,3-4H2,1-2H3

Upstream product

• 53750-66-6 4-chloro-pyridine-2-carbonyl chloride 
• 64-17-5 ethanol 
• 19235-89-3 4-chloro-pyridine-2-carbonitrile 
• 5470-22-4 4-chloropicolinic acid 

Relevant academic research and scientific papers

TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS

A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer as well as sepsis

SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS

The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release- activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I)and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.

PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES

The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.

Use of metal complex compounds as catalysts for oxidation using molecular oxygen or air

Use, as a catalyst for oxidation reactions using molecular oxygen and/or air, of at least one metal complex compound of formula (1) wherein Me is manganese, titanium, iron, cobalt, nickel or copper, X is a coordinating or bridging radical, n and m are each independently of the other an integer having a value of from 1 to 8, p is an integer having a value of from 0 to 32, z is the charge of the metal complex, Y is a counter-ion, q=z/(charge of Y), and L is a ligand of formula (2) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are each independently of the others hydrogen; unsubstituted or substituted C1-C18alkyl or aryl; cyano; halogen; nitro; —COOR12 or —SO3R12 wherein R12 is in each case hydrogen, a cation or unsubstituted or substituted C1-C18alkyl or aryl; —SR13, —SO2R13 or —OR13 wherein R13 is in each case hydrogen or unsubstituted or substituted C1-C18alkyl or aryl; —NR14R15; —(C1-C6alkylene)-NR14R15; —N(+)R14R15R16; —(C1-C6alkylene)-N(+)R14R15R16; —N(R13)—(C1-C6alkylene)-NR14R15; —N[(C1-C6alkylene)-NR14R15]2; —N(R13)—(C1-C6alkylene)-N(+)R14R15R16; —N[(C1-C6alkylene)-N(+)R14R15R16]2; —N(R13)—N—R14R15 or —N(R13)N″R14R15R16, wherein R13 is as defined above and R14, R15 and R16 are each independently of the other(s) hydrogen or unsubstituted or substituted C1-C18alkyl or aryl, or R14 and R15, together with the nitrogen atom linking them, form an unsubstituted or substituted 5-, 6- or 7-membered ring which may contain further hetero atoms. [in-line-formulae][LnMemXp]zYq??(1) [/in-line-formulae]